Skip to main content
logo
Pfizer Inc. (BCBA:PFE)
Argentina flag Argentina · Delayed Price · Currency is ARS
9,940.00
-310.00 (-3.02%)
Oct 8, 2025, 4:58 PM BRT

Revenue

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212013 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 2013 - 2020
Primary Care Revenue
29.21B30.14B
Log In
Log In
Log In
Upgrade
Specialty Care Revenue
17.09B16.65B
Log In
Log In
Log In
Upgrade
Oncology Revenue
16.25B15.61B
Log In
Log In
Log In
Upgrade
Global Pharmaceuticals Business (Biopharma) Revenue
62.55B62.40B
Log In
Log In
Log In
Upgrade
Business Innovation (Pfizer CentreOne) Revenue
1.20B1.15B
Log In
Log In
Log In
Upgrade
Revenue (Other)
86.00M81.00M
Log In
Log In
Log In
Upgrade
Revenue (Total)
63.83B63.63B
Log In
Log In
Log In
Upgrade

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212013 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 2013 - 2020
United States Revenue
38.55B38.69B
Log In
Log In
Log In
Upgrade
Developed Markets Revenue
16.27B16.06B
Log In
Log In
Log In
Upgrade
Emerging Markets Revenue (Post-FY2023 Reporting)
9.01B8.88B
Log In
Log In
Log In
Upgrade
Revenue (Other)
--
Log In
Log In
Log In
Upgrade
Revenue (Total)
63.83B63.63B
Log In
Log In
Log In
Upgrade

Revenue by Geography 2

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212013 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 2013 - 2020
United States Revenue
38.55B38.69B
Log In
Log In
Log In
Upgrade
Revenue (Total)
63.83B63.63B
Log In
Log In
Log In
Upgrade

Revenue by Geography 3

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212013 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 2013 - 2020
United States Revenue
38.55B38.69B
Log In
Log In
Log In
Upgrade
Developed Europe Revenue
--
Log In
Log In
Log In
Upgrade
Developed Rest of World Revenue
--
Log In
Log In
Log In
Upgrade
Emerging Markets Revenue
--
Log In
Log In
Log In
Upgrade
International Revenue
25.28B24.94B
Log In
Log In
Log In
Upgrade
Revenue (Total)
63.83B63.63B
Log In
Log In
Log In
Upgrade

EBT

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212013 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 2013 - 2020
Global Pharmaceuticals Business (Biopharma) Earnings
28.65B28.14B
Log In
Log In
Log In
Upgrade
Other Business Activities Earnings
-6.61B-7.38B
Log In
Log In
Log In
Upgrade

Key Performance Indicators

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212013 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 2013 - 2020
Comirnaty Direct Sales and Alliance Revenue
5.75B5.35B
Log In
Log In
Log In
Upgrade
Eliquis Alliance Revenue and Direct Sales
7.38B7.37B
Log In
Log In
Log In
Upgrade
Prevnar Revenue
--
Log In
Log In
Log In
Upgrade
Paxlovid Revenue
4.35B5.72B
Log In
Log In
Log In
Upgrade
Prevnar Family Revenue
6.40B6.41B
Log In
Log In
Log In
Upgrade
Nurtec ODT/Vydura Revenue
1.34B1.26B
Log In
Log In
Log In
Upgrade
Abrysvo Revenue
828.00M755.00M
Log In
Log In
Log In
Upgrade
Vyndaqel Family Revenue
6.09B5.45B
Log In
Log In
Log In
Upgrade
Xeljanz Revenue
1.12B1.17B
Log In
Log In
Log In
Upgrade
Ibrance Revenue
4.21B4.37B
Log In
Log In
Log In
Upgrade
Vaccines Revenue
--
Log In
Log In
Log In
Upgrade
Internal Medicine Revenue
--
Log In
Log In
Log In
Upgrade
Hospital Revenue
--
Log In
Log In
Log In
Upgrade
Inflammation & Immunology Revenue
--
Log In
Log In
Log In
Upgrade
Rare Disease Revenue
--
Log In
Log In
Log In
Upgrade
Updated Jun 29, 2025. Data Source: Fiscal.ai.